"Neoplasm Staging" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Descriptor ID |
D009367
|
MeSH Number(s) |
E01.789.625
|
Concept/Terms |
Neoplasm Staging- Neoplasm Staging
- Staging, Neoplasm
- Tumor Staging
- Staging, Tumor
- Cancer Staging
- Staging, Cancer
TNM Staging- TNM Staging
- Staging, TNM
- TNM Staging System
- Staging System, TNM
- Staging Systems, TNM
- System, TNM Staging
- Systems, TNM Staging
- TNM Staging Systems
- TNM Classification
- Classification, TNM
- Classifications, TNM
- TNM Classifications
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Staging".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Staging".
This graph shows the total number of publications written about "Neoplasm Staging" by people in this website by year, and whether "Neoplasm Staging" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 10 | 10 |
1996 | 0 | 11 | 11 |
1997 | 1 | 16 | 17 |
1998 | 1 | 17 | 18 |
1999 | 2 | 15 | 17 |
2000 | 0 | 31 | 31 |
2001 | 1 | 20 | 21 |
2002 | 0 | 13 | 13 |
2003 | 2 | 22 | 24 |
2004 | 2 | 17 | 19 |
2005 | 2 | 32 | 34 |
2006 | 0 | 32 | 32 |
2007 | 2 | 46 | 48 |
2008 | 2 | 56 | 58 |
2009 | 1 | 42 | 43 |
2010 | 2 | 61 | 63 |
2011 | 4 | 52 | 56 |
2012 | 2 | 57 | 59 |
2013 | 4 | 61 | 65 |
2014 | 4 | 77 | 81 |
2015 | 2 | 70 | 72 |
2016 | 11 | 57 | 68 |
2017 | 4 | 67 | 71 |
2018 | 4 | 55 | 59 |
2019 | 10 | 57 | 67 |
2020 | 2 | 45 | 47 |
2021 | 1 | 39 | 40 |
2022 | 0 | 25 | 25 |
2023 | 1 | 23 | 24 |
2024 | 15 | 32 | 47 |
2025 | 0 | 16 | 16 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Staging" by people in Profiles.
-
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study. Future Oncol. 2025 May; 21(12):1511-1523.
-
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 05; 23(5):169-191.
-
ACR Appropriateness Criteria® Lung Cancer-Surveillance After Therapy. J Am Coll Radiol. 2025 May; 22(5S):S319-S342.
-
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer. Expert Rev Anticancer Ther. 2025 Jun; 25(6):675-686.
-
Treatment at Academic Facilities Is Associated With Improved Survival in Late-Stage Colonic Neuroendocrine Tumors. J Surg Res. 2025 Jun; 310:111-121.
-
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025. J Natl Compr Canc Netw. 2025 04; 23(4).
-
Clinicopathologic and Molecular Characterization of Gynecologic Carcinosarcomas With a Mesonephric-Like Carcinomatous Component. Am J Surg Pathol. 2025 May 01; 49(5):439-447.
-
Utility of 18F-DCFPyL PET for local staging for high or very high risk prostate cancer for patients undergoing radical prostatectomy. Eur J Nucl Med Mol Imaging. 2025 Jun; 52(7):2335-2342.
-
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. Breast Cancer Res Treat. 2025 May; 211(1):111-119.
-
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial. Gynecol Oncol. 2025 Mar; 194:18-24.